Carnitine and Aspirin
Phase 1Small molecule
Carnitine and Aspirin is one of 42 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPhase 3
Retatrutide
Eli LillyPhase 3
Zilebesiran
Alnylam PharmaceuticalsPhase 3
Repatha
AmgenPreclinical
Praluent
RegeneronPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Benicar
NovartisPreclinical
Farxiga
AstraZenecaPreclinical
Mounjaro
Eli LillyPreclinical
Myrbetriq
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carnitine and Aspirin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TThe Cleveland Clinic